Biotech and Pharma Titans ($AMGN, $PFE, $JNJ, $ATXS) Surge with Impressive Weekly Performance
In the fast-paced realm of biotech and pharmaceuticals, a group of stocks, including giants like Johnson & Johnson (JNJ), Amgen (AMGN), Pfizer (PFE), Astex Pharmaceuticals (ATXS), AnaptysBio (ANAB), and Zymeworks (ZYME), witnessed a noteworthy 8.55% surge in performance over the past week. However, a closer look at various indicators suggests caution, signaling a potential downturn.
1. Negative Outlook and Declining Trends
Fear & Greed Index
The group currently faces a Negative Outlook, as indicated by the Relative Strength Index (RSI). Tickeron, a market analysis platform, predicts a further decline exceeding 4.00% within the next month, with a 62% likelihood. Over the last month, advancing volumes outpaced declining volumes by a ratio of 1.46 to 1.
BollingerBands Indicator
Alarmingly, two stocks within this group confirmed the negative outlook using the BollingerBands indicator, with an average reliability of 72%.
2. Market Capitalization Rollercoaster
The average market capitalization across the group stands at 116 billion USD, ranging from a modest 171 million USD for ATXS to a colossal 381.3 billion USD for JNJ. Interestingly, JNJ experienced a significant market cap drop of $25.6 billion on August 26, 2023, and a staggering decrease of $85.2 billion on May 2, 2023.
3. Price Volatility: Highs and Lows
Weekly Price Movements
The average weekly price growth across the group was a notable 6.74%. For the same cohort, the average monthly and quarterly price growths were 13.14% and 18.65%, respectively. Remarkably, ATXS led the pack with a 36.15% price surge, while JNJ experienced the most significant fall at -1.91%.
Stock-Specific Highlights
- Amgen (AMGN) stood out as a top weekly gainer on November 8, 2023, with a 6.02% jump.
- Pfizer (PFE) faced challenges, being a top loser on September 12, 2023, with a decline of -5.14%.
- Johnson & Johnson (JNJ) also experienced a weekly downturn on August 25, 2023, with a -5.13% fall.
4. Volume Dynamics
Volume Growth Metrics
The average weekly volume growth across the group was 3.4%, with monthly and quarterly growth rates soaring at 127.37% and 71.63%, respectively.
Record-Breaking Volumes
On December 16, 2023, several stocks within the group witnessed extraordinary volume spikes, with AnaptysBio and Astria Therapeutics experiencing daily growths of 319% and 531% of the 65-Day Volume Moving Average, respectively. Zymeworks wasn't far behind, recording a remarkable 272% growth on August 4, 2023.
5. Stock-Specific Momentum Indicators
Amgen (AMGN)
AMGN has recently seen a positive shift in its Momentum Indicator, hinting at a potential upward trend. Tickeron's A.I.dvisor, analyzing 84 similar instances, suggests a 58% probability of a higher trajectory. The stock is currently trading between $333.97 resistance and $306.80 support lines.
Johnson & Johnson (JNJ)
Despite recent challenges, JNJ is showing signs of an upward trend, breaking its lower Bollinger Band on January 24, 2024. Historical data indicates a 60% likelihood of continued upward momentum. JNJ is currently trading between $160.27 support and $150.88 support lines.
Astex Pharmaceuticals (ATXS)
ATXS's Moving Average Convergence Divergence (MACD) turned positive on January 23, 2024. With a remarkable historical accuracy of 90%, the odds favor a continued upward trend. ATXS is currently trading between $14.33 resistance and $10.60 support lines.
In summary, while the recent overall performance of the biotech and pharmaceutical stock group has been impressive, caution is warranted. The negative outlook, declining trends in some stocks, and the unpredictability in market capitalization and volume indicate a complex landscape. Investors should scrutinize individual stock dynamics, considering momentum indicators, and be prepared for potential shifts in the coming weeks.
AMGN in upward trend: 10-day moving average broke above 50-day moving average on January 28, 2025
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on January 28, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
AMGN moved above its 50-day moving average on January 23, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 209 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for AMGN moved out of overbought territory on February 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where AMGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMGN broke above its upper Bollinger Band on February 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMGN's P/B Ratio (24.331) is slightly higher than the industry average of (5.632). P/E Ratio (22.661) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (2.526) is also within normal values, averaging (3.004). Dividend Yield (0.031) settles around the average of (0.164) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (3.643).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor